Elevated plasma endothelial microparticles in multiple sclerosis

被引:245
作者
Minagar, A
Jy, W
Jimenez, JJ
Sheremata, WA
Mauro, LM
Mao, WW
Horstman, LL
Ahn, YS
机构
[1] Univ Miami, Sch Med, Dept Med, Wallace H Coulter Platelet Lab, Miami, FL 33136 USA
[2] Univ Miami, Dept Neurol, Miami, FL 33152 USA
关键词
D O I
10.1212/WNL.56.10.1319
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To assess endothelial dysfunction in patients with MS and to investigate whether plasma from patients with MS induces endothelial cell dysfunction in vitro. Background: Endothelial cell dysfunction may contribute to the pathogenesis of MS. Elevations of soluble adhesion molecules intracellular adhesion molecule, vascular cell adhesion molecule, and platelet-endothelial cell adhesion molecule-1 (CD31) have been reported as markers of blood-brain barrier (BBB) damage in MS, but direct assay of endothelium has been difficult. Endothelial cells release microparticles <-1.5 <mu>m (EMP) during activation or apoptosis. The authors developed a flow cytometric assay of EMP and studied EMP as markers of endothelial damage in MS. Methods: Platelet-poor plasma (PPP) from 50 patients with MS (30 in exacerbation and 20 in remission) and 48 controls were labeled with fluorescein isothiocyanate (FITC)-conjugated anti-CD31 and anti-CD51 (vitronectin receptor) antibodies, and two classes of EMP (CD31+ and CD51+) were assayed by flow cytometry. For in vitro studies, patients' plasma was added to the microvascular endothelial cell (MVEC) culture and release of CD31+ and CD51+ EMP were measured in the supernatant. Results: Plasma from patients in exacerbation had 2.85-fold elevation of CD31+ EMP as compared with healthy controls, returning to near control value during remission. The CD31+ EMP concentration showed a positive association with gadolinium enhancement in patients with MS. In contrast, CD51+ EMP remained elevated in both exacerbation and remission. This suggests that CD31+ EMP is a marker of acute injury, whereas CD51+ EMP reflects chronic injury of endothelium. MS plasma induced release of both CD31+ and CD51+ EMP from MVEC culture in vitro. Conclusion: Endothelial dysfunction is evident during exacerbation of MS, evidenced by shedding of EMP expressing PECAM-1 (CD31). The in vitro data indicate contribution of one or more plasma factors in endothelial dysfunction of MS.
引用
收藏
页码:1319 / 1324
页数:6
相关论文
共 27 条
[1]   MONOCLONAL-ANTIBODY TO MURINE PECAM-1 (CD31) BLOCKS ACUTE-INFLAMMATION IN-VIVO [J].
BOGEN, S ;
PAK, J ;
GARIFALLOU, M ;
DENG, XH ;
MULLER, WA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :1059-1064
[2]   Mechanisms of immune injury in multiple sclerosis [J].
Brosnan, CF ;
Raine, CS .
BRAIN PATHOLOGY, 1996, 6 (03) :243-257
[3]   THE ADHESION MOLECULE AND CYTOKINE PROFILE OF MULTIPLE-SCLEROSIS LESIONS [J].
CANNELLA, B ;
RAINE, CS .
ANNALS OF NEUROLOGY, 1995, 37 (04) :424-435
[4]  
Chofflon M, 1992, Eur Cytokine Netw, V3, P523
[5]   In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant [J].
Combes, V ;
Simon, AC ;
Grau, GE ;
Arnoux, D ;
Camoin, L ;
Sabatier, F ;
Mutin, M ;
Sanmarco, M ;
Sampol, J ;
Dignat-George, F .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (01) :93-102
[6]   CIRCULATING, SOLUBLE ADHESION PROTEINS IN CEREBROSPINAL-FLUID AND SERUM OF PATIENTS WITH MULTIPLE-SCLEROSIS - CORRELATION WITH CLINICAL ACTIVITY [J].
DOREDUFFY, P ;
NEWMAN, W ;
BALABANOV, R ;
LISAK, RP ;
MAINOLFI, E ;
ROTHLEIN, R ;
PETERSON, M .
ANNALS OF NEUROLOGY, 1995, 37 (01) :55-62
[7]   Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS [J].
Elovaara, I ;
Lällä, M ;
Spåre, E ;
Lehtimäki, T ;
Dastidar, P .
NEUROLOGY, 1998, 51 (06) :1703-1708
[8]  
HAMILTON KK, 1990, J BIOL CHEM, V265, P3809
[9]   CIRCULATING ADHESION MOLECULES AND TUMOR-NECROSIS-FACTOR RECEPTOR IN MULTIPLE-SCLEROSIS - CORRELATION WITH MAGNETIC-RESONANCE-IMAGING [J].
HARTUNG, HP ;
REINERS, K ;
ARCHELOS, JJ ;
MICHELS, M ;
SEELDRAYERS, P ;
HEIDENREICH, F ;
PFLUGHAUPT, KW ;
TOYKA, KV .
ANNALS OF NEUROLOGY, 1995, 38 (02) :186-193
[10]  
LEE SC, 1993, J IMMUNOL, V150, P2659